BridgeBio Oncology Therapeutics, Inc. (BBOT) — Strategic Asset Allocation Index
BridgeBio Oncology Therapeutics, Inc. (BBOT) has a Strategic Asset Allocation Index of 36.7% as of March 2026. Strategic assets (PP&E of $- plus long-term investments of $136.62 Million) total $136.62 Million, measured against net assets of $372.28 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See BridgeBio Oncology Therapeutics, Inc. free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
SAAI
Strategic Assets
PP&E
Net Assets
Annual Strategic Asset Allocation Index for BridgeBio Oncology Therapeutics, Inc. (None–None)
The table below presents the year-by-year Strategic Asset Allocation Index for BridgeBio Oncology Therapeutics, Inc. from None to None, covering 0 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see BBOT market cap.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|